Search

Your search keyword '"Marzolini M"' showing total 22 results
Start Over Author "Marzolini M"
22 results on '"Marzolini M"'

1. P1460: SAFETY AND EFFICACY FINDINGS OF AUTO1, A FAST-OFF RATE CD19 CAR, IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA

Author

Roddie, C., primary, Dias, J., additional, O’Reilly, M., additional, Green, L., additional, Vaughan, M., additional, Agliardi, G., additional, Garcia, J., additional, Lewin, E., additional, Lowdell, M., additional, Mitsikakou, M., additional, Charalambous, E., additional, Hotblack, A., additional, Dreau, H., additional, Marzolini, M., additional, Wood, L., additional, Every-Clayton, C., additional, Lal, A., additional, Ngai, Y., additional, Popova, B., additional, Malhi, A., additional, Kunaseelan, S., additional, Spanswick, V., additional, Lowe, H., additional, Ensell, L., additional, Hartley, J., additional, Domning, S., additional, Thorne, L., additional, Hyare, H., additional, Murphy, P., additional, Linch, D., additional, Fox, C., additional, Peggs, K., additional, Cwynarski, K., additional, and Pule, M., additional

Published
2022
Full Text
View/download PDF

2. P1459: SAFETY AND EFFICACY FINDINGS OF AUTO1, A FAST-OFF RATE CD19 CAR, IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA (B-NHL), AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) / SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Author

Roddie, C., primary, Dias, J., additional, O’Reilly, M., additional, Mitsikakou, M., additional, Charalambous, E., additional, Green, L., additional, Vaughan, M., additional, Agliardi, G., additional, Garcia, J., additional, Lewin, E., additional, Lowdell, M., additional, Marzolini, M., additional, Wood, L., additional, Holmes, H., additional, Ngai, Y., additional, Popova, B., additional, Wilson, W., additional, Kunaseelan, S., additional, Spanswick, V., additional, Lowe, H., additional, Ensell, L., additional, Hartley, J., additional, Domning, S., additional, Morley, S., additional, Marafioti, T., additional, Bloor, A., additional, Irvine, D., additional, Orchard, K., additional, Khwaja, A., additional, Linch, D., additional, Pule, M., additional, and Peggs, K., additional

Published
2022
Full Text
View/download PDF

5. 890MO Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL

Author

Tholouli, E., primary, Osborne, W., additional, Bachier, C., additional, Ramakrishnan, A., additional, Marzolini, M., additional, Irvine, D., additional, McSweeney, P., additional, Bartlet, N., additional, Zhang, Y., additional, Thomas, S., additional, Al-Hajj, M., additional, Pule, M., additional, Jonnaert, M., additional, Peddareddigari, V., additional, Khokhar, N., additional, Chen, R., additional, and Ardesha, K., additional

Published
2020
Full Text
View/download PDF

7. Efficacy and tolerability of gabapentin (GBP) versus valproato (VPA) as add-on therapy to neuroleptics in the treatment of acute maniac symptoms

Author

Alberti, GG, Garini, R, Marzolini, M, Beltz, J, Felcher, A, Greco, MI, Maresca, G, Alberti, G, Garini, R, Marzolini, M, Beltz, J, Felcher, A, Greco, M, and Maresca, G

Subjects
manic synptoms, pharmacotherapy, gabapentin (GBP) versus valproate (VPA)
Abstract

The published reports yelded promising results, but the interpretation of the therapeutic role of GBP in mania was difficult because the drug was already associated to a wide range of other agents, whose dose was not manteined uncharged during the study. The objective of our study was to assess the efficacy and safety of GBP versus VPA in adjunct to a fixed dose of neuroleptics (NL) in patients hospetalized because of an evidence of acute manic synptoms.

Published
1998

8. Gabapentin (GBP) versus Valproato (VPA) as an adjunct to neuroleptics in the treatment of acute symptoms

Author

Alberti, GG, Garini, R, Marzolini, M, Beltz, J, Felcher, A, Greco, MI, Maresca, G, Alberti, G, Garini, R, Marzolini, M, Beltz, J, Felcher, A, Greco, M, and Maresca, G

Subjects
acute manic symptoms, pharmacotherapy, gabapentin (GBP) versus valproato (VPA)
Abstract

This published report yelded promising results, but the interpretations of therapeutic role of GBP in mania was difficult because the drug was always associated to a wide range of other agents, whose dose was not mainteined uncharged during the study. The objective of our study was to asses the efficacy and safety of GBP versus VPA in adjunct of a fixed dose of neuroleptics in patients hospedalized because of an outburst of acute manic symptoms.

Published
1998

13. Efficacy and tolerability of gabapentin (GBP) versus valproato (VPA) as add-on therapy to neuroleptics in the treatment of acute maniac symptoms

Author

Alberti, G, Garini, R, Marzolini, M, Beltz, J, Felcher, A, Greco, M, Maresca, G, Alberti, GG, Greco, MI, Alberti, G, Garini, R, Marzolini, M, Beltz, J, Felcher, A, Greco, M, Maresca, G, Alberti, GG, and Greco, MI

Abstract

The published reports yelded promising results, but the interpretation of the therapeutic role of GBP in mania was difficult because the drug was already associated to a wide range of other agents, whose dose was not manteined uncharged during the study. The objective of our study was to assess the efficacy and safety of GBP versus VPA in adjunct to a fixed dose of neuroleptics (NL) in patients hospetalized because of an evidence of acute manic synptoms.

Published
1998

14. Gabapentin (GBP) versus Valproato (VPA) as an adjunct to neuroleptics in the treatment of acute symptoms

Author

Alberti, G, Garini, R, Marzolini, M, Beltz, J, Felcher, A, Greco, M, Maresca, G, Alberti, GG, Greco, MI, Alberti, G, Garini, R, Marzolini, M, Beltz, J, Felcher, A, Greco, M, Maresca, G, Alberti, GG, and Greco, MI

Abstract

This published report yelded promising results, but the interpretations of therapeutic role of GBP in mania was difficult because the drug was always associated to a wide range of other agents, whose dose was not mainteined uncharged during the study. The objective of our study was to asses the efficacy and safety of GBP versus VPA in adjunct of a fixed dose of neuroleptics in patients hospedalized because of an outburst of acute manic symptoms.

Published
1998

20. Outcome of high-grade lymphoma patients treated with cd19 car-t-updated real-world experience in the UK

Author

Kuhnl, A., Roddie, C., Tholouli, E., Menne, T., Kim Linton, Lugthart, S., Changanti, S., Kirkwood, A., Sanderson, R., Reilley, M. O., Norman, J., Osborne, W., Patel, A., Chavda, N., Malladi, R., Jones, C., Patten, P., Neill, L., Martinez-Cibrian, N., Smith, K., John Radford, Robinson, S., Iyengar, S., Ayse Latif, Burton, C., Uttenthal, B., Stewart, O., Marzolini, M., Townsend, W., Ardeshna, K., Ardavan, A., Robinson, K., Pagliuca, T., Bowles, K., Collins, G., Rees Johnson, and Mcmillan, A.

21. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.

Author

Roddie C, Neill L, Osborne W, Iyengar S, Tholouli E, Irvine D, Chaganti S, Besley C, Bloor A, Jones C, Uttenthal B, Johnson R, Sanderson R, Cheok K, Marzolini M, Townsend W, O'Reilly M, Kirkwood AA, and Kuhnl A

Subjects
Adult, Humans, Neoplasm Recurrence, Local, Bridge Therapy, Adaptor Proteins, Signal Transducing, Antigens, CD19 therapeutic use, Receptors, Chimeric Antigen, Lymphoma, Large B-Cell, Diffuse drug therapy
Abstract

The impact of bridging therapy (BT) on CD19-directed chimeric antigen receptor T-cell (CD19CAR-T) outcomes in large B-cell lymphoma (LBCL) is poorly characterized. Current practice is guided through physician preference rather than established evidence. Identification of effective BT modalities and factors predictive of response could improve both CAR-T intention to treat and clinical outcomes. We assessed BT modality and response in 375 adult patients with LBCL in relation to outcomes after axicabtagene ciloleucel (Axi-cel) or tisagenlecleucel (Tisa-cel) administration. The majority of patients received BT with chemotherapy (57%) or radiotherapy (17%). We observed that BT was safe for patients, with minimal morbidity or mortality. We showed that complete or partial response to BT conferred a 42% reduction in disease progression and death after CD19CAR-T therapy. Multivariate analysis identified several factors associated with likelihood of response to BT, including response to last line therapy, the absence of bulky disease, and the use of polatuzumab-containing chemotherapy regimens. Our data suggested that complete or partial response to BT may be more important for Tisa-cel than for Axi-cel, because all patients receiving Tisa-cel with less than partial response to BT experienced frank relapse within 12 months of CD19CAR-T infusion. In summary, BT in LBCL should be carefully planned toward optimal response and disease debulking, to improve patient outcomes associated with CD19CAR-T. Polatuzumab-containing regimens should be strongly considered for all suitable patients, and failure to achieve complete or partial response to BT before Tisa-cel administration may prompt consideration of further lines of BT where possible., (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)

Published
2023
Full Text
View/download PDF

22. Diffusion-weighted MRI compared to FDG PET-CT in the staging and response assessment of Hodgkin lymphoma.

Author

Marzolini M, Wong WL, Ardeshna K, Padhani A, and D'Sa S

Subjects
Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bleomycin therapeutic use, Cyclophosphamide therapeutic use, Diffusion Magnetic Resonance Imaging methods, Doxorubicin therapeutic use, Etoposide therapeutic use, Fluorodeoxyglucose F18, Hodgkin Disease diagnostic imaging, Hodgkin Disease drug therapy, Humans, Male, Multimodal Imaging methods, Neoplasm Staging, Positron-Emission Tomography, Prednisone therapeutic use, Procarbazine therapeutic use, Radiopharmaceuticals, Tomography, X-Ray Computed, Treatment Outcome, Vincristine therapeutic use, Hodgkin Disease pathology
Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results